Display options
Cite
Cren PY, Lebellec L, Ryckewaert T, et al. Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. Front Oncol. 2020;10:594445doi: 10.3389/fonc.2020.594445.
Cren, P. Y., Lebellec, L., Ryckewaert, T., & Penel, N. (2020). Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. Frontiers in oncology, 10594445. https://doi.org/10.3389/fonc.2020.594445
Cren, Pierre-Yves, et al. "Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials." Frontiers in oncology vol. 10 (2020): 594445. doi: https://doi.org/10.3389/fonc.2020.594445
Cren PY, Lebellec L, Ryckewaert T, Penel N. Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. Front Oncol. 2020 Nov 24;10:594445. doi: 10.3389/fonc.2020.594445. eCollection 2020. PMID: 33330082; PMCID: PMC7732617.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2020 Nov 24;10:594445. doi: 10.3389/fonc.2020.594445. eCollection 2020.

Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.

Frontiers in oncology

Pierre-Yves Cren, Loïc Lebellec, Thomas Ryckewaert, Nicolas Penel

Affiliations

  1. Lille University, Medical School, Lille, France.
  2. Medical Oncology Unit, Tourcoing Hospital, Tourcoing, France.
  3. Medical Oncology Department, Centre Oscar Lambret, Lille, France.

PMID: 33330082 PMCID: PMC7732617 DOI: 10.3389/fonc.2020.594445

Abstract

We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phase II trials with limited samples and without stratification according to histological subtypes, therefore interpretation of such trials is very challenging. On the contrary, pazopanib, regorafenib, and sorafenib have been assessed using double-blind placebo-controlled randomized phase II or phase III trials. Compared to placebo, sorafenib demonstrates activity in desmoid-type fibromatosis patients. Based on results of phase 3 trial, pazopanib had obtained approval for treatment of pretreated non-adipocytic soft tissue sarcoma. Regorafenib is currently assessed in several clinical settings and provides significant improvement of progression-free survival in pre-treated non-adipocytic soft tissue sarcoma and in advanced pretreated osteosarcoma. Multikinase inhibitors are a breakthrough in sarcoma management. Many trials are ongoing. Nevertheless, predictive factors are still missing.

Copyright © 2020 Cren, Lebellec, Ryckewaert and Penel.

Keywords: Choi criteria; clinical trial; multikinase inhibitor; non-adipocytic soft tissue sarcoma; sarcoma

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer GG declared a

References

  1. J Clin Oncol. 2019 Jun 1;37(16):1424-1431 - PubMed
  2. Oncologist. 2019 Jan;24(1):20-e29 - PubMed
  3. Lancet. 2012 May 19;379(9829):1879-86 - PubMed
  4. Sarcoma. 2015;2015:532478 - PubMed
  5. Lancet Oncol. 2017 Oct;18(10):1397-1410 - PubMed
  6. J Cell Physiol. 2013 Jun;228(6):1344-50 - PubMed
  7. Ann Oncol. 2012 Mar;23(3):785-790 - PubMed
  8. J Clin Oncol. 2009 Jul 1;27(19):3154-60 - PubMed
  9. Cancer. 2012 Feb 1;118(3):770-6 - PubMed
  10. Cancer. 2017 Dec 1;123(23):4640-4647 - PubMed
  11. Int J Cancer. 2017 Oct 1;141(7):1469-1477 - PubMed
  12. Clin Cancer Res. 2019 Mar 1;25(5):1479-1485 - PubMed
  13. Eur J Cancer. 2017 Sep;83:177-184 - PubMed
  14. Cancer. 2011 Nov 1;117(21):4939-47 - PubMed
  15. Clin Cancer Res. 2013 Dec 15;19(24):6902-11 - PubMed
  16. Am J Surg Pathol. 2016 May;40(5):645-55 - PubMed
  17. Oncologist. 2015 Nov;20(11):1245-6 - PubMed
  18. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95 - PubMed
  19. Lancet Oncol. 2019 Jun;20(6):837-848 - PubMed
  20. Ann Oncol. 2010 May;21(5):1130-1 - PubMed
  21. Clin Med Insights Oncol. 2013 Oct 29;7:269-77 - PubMed
  22. Lancet Oncol. 2019 Jan;20(1):134-144 - PubMed
  23. Curr Opin Oncol. 2016 Sep;28(5):437-40 - PubMed
  24. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78 - PubMed
  25. Acta Oncol. 2015;54(8):1195-201 - PubMed
  26. Gynecol Oncol. 2012 Apr;125(1):136-40 - PubMed
  27. Lancet Oncol. 2019 Sep;20(9):1252-1262 - PubMed
  28. Eur J Cancer. 2020 Jan;125:31-37 - PubMed
  29. BMC Cancer. 2018 Oct 1;18(1):937 - PubMed
  30. Ann Oncol. 2017 Jan 1;28(1):121-127 - PubMed
  31. BMC Cancer. 2014 Oct 10;14:756 - PubMed
  32. Ann Surg Oncol. 2014 May;21(5):1616-23 - PubMed
  33. J Clin Oncol. 2009 Jul 1;27(19):3126-32 - PubMed
  34. Oncologist. 2012;17(2):260-6 - PubMed
  35. Mol Cancer Ther. 2011 May;10(5):861-73 - PubMed
  36. Ann Surg Oncol. 2019 May;26(5):1332-1339 - PubMed
  37. Lancet Oncol. 2016 Dec;17(12):1732-1742 - PubMed
  38. Pediatr Blood Cancer. 2019 Dec;66(12):e27987 - PubMed
  39. Oncologist. 2019 Jun;24(6):857-863 - PubMed
  40. Cancer. 2015 Sep 1;121(17):2933-41 - PubMed
  41. Eur J Cancer. 2019 Jan;106:225-233 - PubMed
  42. Eur J Cancer. 2002 Mar;38(4):543-9 - PubMed
  43. Transl Androl Urol. 2012 Dec;1(4):207-8 - PubMed
  44. Lancet Oncol. 2019 Jan;20(1):120-133 - PubMed
  45. J Clin Oncol. 2013 Jun 20;31(18):2296-302 - PubMed
  46. Cancer. 2013 Jul 15;119(14):2639-44 - PubMed
  47. Br J Cancer. 2012 Aug 7;107(4):639-45 - PubMed
  48. N Engl J Med. 2018 Dec 20;379(25):2417-2428 - PubMed
  49. Br J Cancer. 2014 Dec 9;111(12):2254-61 - PubMed
  50. BMC Cancer. 2016 Sep 23;16(1):750 - PubMed
  51. Ann Oncol. 2014 Mar;25(3):719-724 - PubMed
  52. Lancet Oncol. 2015 Jan;16(1):98-107 - PubMed
  53. Invest New Drugs. 2011 Jun;29(3):481-8 - PubMed
  54. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67 - PubMed
  55. J Adolesc Young Adult Oncol. 2020 Jun;9(3):449-452 - PubMed
  56. Ann Surg Oncol. 2015 Sep;22(9):2839-45 - PubMed
  57. Radiat Oncol. 2016 Jun 03;11:77 - PubMed
  58. Invest New Drugs. 2013 Dec;31(6):1626-7 - PubMed
  59. J Clin Oncol. 2015 Sep 1;33(25):2797-802 - PubMed
  60. Clin Cancer Res. 2011 Jun 15;17(12):4082-90 - PubMed
  61. Ann Oncol. 2012 Dec;23(12):3171-3179 - PubMed
  62. Sarcoma. 2016;2016:4592768 - PubMed
  63. Lancet Oncol. 2019 Jul;20(7):1023-1034 - PubMed
  64. J Clin Oncol. 2005 Oct 1;23(28):7135-42 - PubMed
  65. Cancer Sci. 2003 Feb;94(2):200-4 - PubMed
  66. Cancers (Basel). 2018 Feb 17;10(2): - PubMed
  67. Curr Opin Oncol. 2017 Jul;29(4):268-274 - PubMed
  68. Clin Cancer Res. 2018 Nov 1;24(21):5233-5238 - PubMed
  69. Ann Oncol. 2013 Jan;24(1):257-63 - PubMed
  70. Cancer. 2017 Jun 15;123(12):2294-2302 - PubMed
  71. Cancer Sci. 2018 Apr;109(4):1207-1219 - PubMed
  72. Lancet Oncol. 2015 May;16(5):531-40 - PubMed
  73. Ann Oncol. 2013 Apr;24(4):1093-8 - PubMed
  74. J Clin Oncol. 2015 Apr 1;33(10):1180-5 - PubMed
  75. Clin Cancer Res. 2017 Aug 1;23(15):4027-4034 - PubMed
  76. Invest New Drugs. 2014 Apr;32(2):369-76 - PubMed
  77. Ann Oncol. 2012 Feb;23(2):508-16 - PubMed
  78. Invest New Drugs. 2018 Jun;36(3):468-475 - PubMed
  79. PLoS One. 2012;7(2):e26331 - PubMed
  80. Lung Cancer. 2014 Aug;85(2):224-9 - PubMed
  81. Lancet Oncol. 2019 Sep;20(9):1263-1272 - PubMed
  82. Mol Cancer Ther. 2014 Nov;13(11):2527-36 - PubMed
  83. Ann Oncol. 2015 Oct;26(10):2168-73 - PubMed
  84. Eur J Cancer. 2020 Feb;126:45-55 - PubMed

Publication Types